Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl)cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).pelzont should be used in patients in combination with 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with pelzont.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol phosphate from haemophilus influenzae type b as prp-ompc, outer membrane protein complex of neisseria meningitidis (outer membrane protein complex of the b11 strain of neisseria meningitidis subgroup b), adsorbed hepatitis b surface antigen produced in recombinant yeast cells (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vaccines - procomvax is indicated for vaccination against invasive disease caused by haemophilus influenzae type b and against infection caused by all known subtypes of hepatitis b virus in infants 6 weeks to 15 months of age.,

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp and dohme b.v - ribavirin - hepatitis c, chronic - antivirals for systemic use, antivirals for treatment of hcv infections - rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) in adults.rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus, tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a pparγ agonist (i.e. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (pparγ) agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp dohme ltd. - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - tredaptive is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).tredaptive should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with tredaptive.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp dohme ltd - laropiprant, nicotinic acid - dyslipidemias - lipid modifying agents - trevaclyn is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of low-density-lipoprotein (ldl) cholesterol and triglycerides and low high-density-lipoprotein (hdl) cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).trevaclyn should be used in patients in combination with 3-hydroxy-3-methyl-glutaryl-co-enzyme-a (hmg-coa)-reductase inhibitors (statins), when the cholesterol-lowering effect of hmg-coa-reductase-inhibitor monotherapy is inadequate. it can be used as monotherapy only in patients in whom hmg-coa-reductase inhibitors are considered inappropriate or not tolerated. diet and other non-pharmacological treatments (e.g. exercise, weight reduction) should be continued during therapy with trevaclyn.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfate, tazobactam sodium - bacterial infections - antibacterials for systemic use, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap).consideration should be given to official guidance on the appropriate use of antibacterial agents.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

merck sharp dohme limited - vorapaxar sulfate - myocardial infarction - antithrombotic agents - zontivityis indicated for the reduction of atherothrombotic events in adult patients with- a history of myocardial infarction (mi)co-administered with acetylsalicylic acid (asa) and, where appropriate, clopidogrel; or- symptomatic peripheral arterial disease(pad), co-administered with acetylsalicylic acid (asa) or, where appropriate, clopidogrel.

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - efavirenz - capsule - 100mg